The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms-Reference-Cited by-同舟云学术

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

Published:2017-06-16 Issue:9 Volume:6 Page:e1339853
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Pazina Tatiana¹²,James Ashley M.¹,MacFarlane Alexander W.¹,Bezman Natalie A.³,Henning Karla A.³,Bee Christine³,Graziano Robert F.³,Robbins Michael D.³,Cohen Adam D.⁴,Campbell Kerry S.¹^ORCID

Affiliation:

1. Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA

2. Federal State Budgetary Scientific Institution “Institute of Experimental Medicine,” St. Petersburg, Russia

3. Bristol-Myers Squibb, Princeton, NJ, USA

4. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1339853

Reference49 articles.

1. Multiple Myeloma

2. Latest advances and current challenges in the treatment of multiple myeloma

3. Monoclonal antibodies: versatile platforms for cancer immunotherapy

4. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising immunotherapeutic approaches for primary effusion lymphoma;Exploration of Targeted Anti-tumor Therapy;2024-06-26

2. Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity;Cancer Immunology Research;2024-05-30

3. The numerous facets of 1q21⁺ in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review);Oncology Letters;2024-04-09

4. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma;Journal for ImmunoTherapy of Cancer;2024-04

5. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study;Annals of Hematology;2024-03-16